Nurix Therapeutics NRIX 深 沪
等待开盘 10-03 09:30:00 美东时间
9.08
-0.320
-3.40%
华盛通- 最 高9.69
- 今 开9.44
- 成交量 63.50万股
- 最 低 8.85
- 昨 收 9.40
- 总市值 6.94亿
- 52周最高 29.56
- 市盈率 静 --
- 换手率 0.83%
- 52周最低 8.18
- 委 比 -0.59%
- 总股本 7644.94万
- 历史最高 52.38
- 量 比 0.41
- 振 幅 8.94%
- 历史最低 4.22
- 每 手 1
- 风险率 5.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nurix And Gilead Advance IRAK4 Degrader GS-6791 Into Clinical Trials After Preclinical Results In Skin Disease
Nurix Therapeutics, Inc. (NASDAQ:NRIX) today announced the presentation of preclinical data from GS-6791/NX-0479, a novel IRAK4 protein degrader discovered as part of the company's ongoing research collaboration with
09-17 19:10
Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis
Nurix Therapeutics and Gilead Sciences have advanced GS-6791, a novel IRAK4 degrader, into clinical testing for inflammatory diseases. Preclinical data, presented at the EADV Congress, demonstrate GS-6791's ability to degrade IRAK4, inhibiting IL-1 and IL-36 responses and reducing disease in a model of atopic dermatitis. Serving as a potent, selective, and oral therapy, GS-6791 has shown promise in treating inflammatory conditions. The ongoing Ph...
09-17 11:00
Nurix Therapeutics to Discuss Bexobrutideg Developments
Nurix Therapeutics ( ($NRIX) ) has issued an update. Nurix Therapeutics announc...
09-03 20:29
Nurix Therapeutics to Participate in Upcoming Investor Conferences
Nurix Therapeutics announced that its executives will participate in several investor conferences in September, including the Wells Fargo Healthcare Conference, H.C. Wainwright Annual Global Investment Conference, RW Baird Healthcare Conference, Morgan Stanley Healthcare Conference, and Stifel Virtual Immunology & Inflammation Forum. The events will feature fireside chats and corporate presentations, accessible via the Investors section of Nurix'...
08-28 20:01
智翔金泰GR1802注射液启动过敏性鼻炎适应症III期临床试验
GENRIX BIO 8月13日，智翔金泰（股票代码：688443）发布公告，公司自主研发的GR1802注射液针对过敏性鼻炎适应症的II期临床试验已达到主要疗效...
08-13 17:05
6 Analysts Assess Nurix Therapeutics: What You Need To Know
6 analysts have expressed a variety of opinions on Nurix Therapeutics (NASDAQ:N...
08-01 05:00
美股大行评级 | 巴克莱上调 Robinhood目标价至102美元；瑞银下调京东目标价从58美元至50美元
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从25美元升至29美元；摩根士丹利：维持Legend Biotech"超配"评级，目标价从80美元升至81美元
07-11 09:04
美股盘前丨三大股指期货盘前涨跌不一 达美航空涨超13%
【时政新闻】 美国上周初请失业金人数22.7万人，前值23.3万人； 商务部：中美双方在多个层级就经贸领域各自关切保持密切沟通； 外交部：美对铜加征关税不符合任...
07-10 20:33
Nurix Therapeutics Q2 EPS $(0.52) Beats $(0.75) Estimate, Sales $44.056M Beat $17.009M Estimate
Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.75) by 30.76 percent. This is a 26.76 percent increase over losses of $(0.71) per share
07-10 04:02
Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Nurix Therapeutics reported strong financial results for Q2 2025, including $44.1M revenue and $485.8M in cash and marketable securities. Key milestones include positive data for bexobrutideg in CLL and WM, Sanofi extending its STAT6 collaboration with a $15M fee, and FDA clearance for GS-6791/NX-0479's IND. Nurix's pipeline advancements highlight its focus on targeted protein degradation therapies for cancer and inflammatory diseases.
07-09 20:01
